ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2019

Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study.

Takeshi Osonoi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.